Hospira Inc. (NYSE:HSP) announced U.S. Food and Drug Administration (FDA) approval of gemcitabine injection, a solution form of the drug. The solution presentations include 200 mg, 1 gm and 2 gm with a concentration of 38 mg/ml. The oncology medication had U.S. sales of more than $750 million in 2010, led by Eli Lilly’s Gemzar®. Hospira expects to launch the product in early September.

Hospira, Inc., a specialty pharmaceutical and medication delivery company, develops, manufactures, and markets pharmaceuticals and medication delivery systems in the United States and internationally.


Read more at: http://pennyomega.com/?p=16615